1-8 of 8
Ludmila Prudkin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B187: Prevalence of MET copy number variation, MET expression and MET related genomic alterations in all solid tumors pre-screening program. VHIO experience

Analía Azaro, Guillem Argilés, María Alsina, Elena Elez, Teresa Macarulla, Cristina Cruz, Donatella Marino, Cinta Hierro, Susana Cedres, Alejandro Navarro, María Ochoa de Olza, Irene Braña, Juan Martín-Liberal, Marta Vilaró, Debora Moreno, Paola Martínez, María Díaz, Ana Vivancos, Jordi Rodón, Josep Tabernero, Ludmila Prudkin, Paolo Nuciforo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B187.
https://doi.org/10.1158/1535-7163.TARG-15-B187
Published: 01 December 2015
View article titled, Abstract B187: Prevalence of MET copy number variation, MET expression and MET related genomic alterations in all solid tumors pre-screening program. VHIO experience
Journal Articles

Abstract C114: Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation.

Violeta Serra, Ana Vivancos, Xose Puente, Enriqueta Felip, Daniel Silberschmidt, Ginevra Caratù, Josep-Lluis Parra, Leticia De Mattos-Arruda, Judit Grueso, Javier Hernández-Losa, Joaquín Arribas, Ludmila Prudkin, Paolo Nuciforo, Maurizio Scaltriti, Joan Seoane, José Baselga
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C114.
https://doi.org/10.1158/1535-7163.TARG-13-C114
Published: 01 November 2013
View article titled, Abstract C114: Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation.
Journal Articles

Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials

Rodrigo Dienstmann, Danila Serpico, Jordi Rodon, Cristina Saura, Teresa Macarulla, Elena Elez, Maria Alsina, Jaume Capdevila, Jose Perez-Garcia, Gessamí Sánchez-Ollé, Claudia Aura, Ludmila Prudkin, Stefania Landolfi, Javier Hernández-Losa, Ana Vivancos, Josep Tabernero
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (9): 2062–2071.
https://doi.org/10.1158/1535-7163.MCT-12-0290
Published: 06 September 2012
View article titled, Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials
Open the PDF for Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials in another window
Journal Articles

Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer

Maurizio Scaltriti, Violeta Serra, Emmanuel Normant, Marta Guzman, Olga Rodriguez, Alice R. Lim, Kelly L. Slocum, Kip A. West, Varenka Rodriguez, Ludmila Prudkin, José Jimenez, Claudia Aura, José Baselga
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (5): 817–824.
https://doi.org/10.1158/1535-7163.MCT-10-0966
Published: 08 May 2011
View article titled, Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
Open the PDF for Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B144: NVP‐BEZ235, a dual inhibitor of PI3K and mTOR, induces MAPK phosphorylation in HER2‐positive cells

Violeta Serra Elizalde, Pieter JA Eichhorn, Maurizio Scaltriti, Ludmila Prudkin, Olga Rodriguez, Marta Guzman, José Baselga
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B144.
https://doi.org/10.1158/1535-7163.TARG-09-B144
Published: 10 December 2009
View article titled, Abstract B144: NVP‐BEZ235, a dual inhibitor of PI3K and mTOR, induces MAPK phosphorylation in HER2‐positive cells
Journal Articles

Abstract B250: Clinical benefit of lapatinib‐based therapy in patients with HER2‐positive breast tumors expressing p95HER2

Maurizio Scaltriti, Sarat Chandarlapaty, Ludmila Prudkin, Claudia Aura, Jose Jimenez, Pierdavide Angelini, Cathrine Ellis, Robert Gagnon, Neil Rosen, Jose Baselga
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B250.
https://doi.org/10.1158/1535-7163.TARG-09-B250
Published: 10 December 2009
View article titled, Abstract B250: Clinical benefit of lapatinib‐based therapy in patients with HER2‐positive breast tumors expressing p95HER2
Journal Articles

A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras

Yanan Yang, Marie Wislez, Nobukazu Fujimoto, Ludmila Prudkin, Julie G. Izzo, Futoshi Uno, Lin Ji, Amy E. Hanna, Robert R. Langley, Diane Liu, Faye M. Johnson, Ignacio Wistuba, Jonathan M. Kurie
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (4): 952–960.
https://doi.org/10.1158/1535-7163.MCT-07-2045
Published: 15 April 2008
View article titled, A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant <em>K-ras</em>
Open the PDF for A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant <em>K-ras</em> in another window
Journal Articles

Angiogenesis in non-small cell lung cancer (NSCLC): Gender differences in tumor and circulating angiogenic factors

Emer Hanrahan, Ludmila Prudkin, Heather Yan Lin, Carmen Behrens, Erminia Massarelli, Matthew Herynk, Danny Du, Marie Wislez, Jonathan Kurie, Roy Herbst, J. Jack Lee, Ignacio Wistuba, John Heymach
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A24.
Published: 01 November 2007
View article titled, Angiogenesis in non-small cell lung cancer (NSCLC): Gender differences in tumor and circulating angiogenic factors